NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, Price Target & More

$3.30 -0.10 (-2.94 %)
(As of 04/26/2018 07:36 AM ET)
Previous Close$3.40
Today's Range$3.29 - $3.43
52-Week Range$2.88 - $5.18
Volume21,600 shs
Average Volume59,149 shs
Market Capitalization$64.84 million
P/E Ratio-12.69
Dividend YieldN/A
Beta1.87

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BCLI
CUSIPN/A
Phone201-488-0460

Debt

Debt-to-Equity RatioN/A
Current Ratio1.74%
Quick Ratio1.74%

Price-To-Earnings

Trailing P/E Ratio-12.69
Forward P/E Ratio-5.00
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book10.65

Profitability

EPS (Most Recent Fiscal Year)($0.26)
Net Income$-4,950,000.00
Net MarginsN/A
Return on Equity-74.47%
Return on Assets-49.79%

Miscellaneous

Employees24
Outstanding Shares19,070,000

How to Become a New Pot Stock Millionaire

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) posted its quarterly earnings data on Thursday, March, 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.11. View Brainstorm Cell Therapeutics' Earnings History.

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Brainstorm Cell Therapeutics.

What price target have analysts set for BCLI?

1 equities research analysts have issued 1 year price targets for Brainstorm Cell Therapeutics' stock. Their predictions range from $9.00 to $9.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $9.00 in the next year. View Analyst Ratings for Brainstorm Cell Therapeutics.

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:
  • Dr. Irit Arbel DSc, Founder & Chairperson (Age 58)
  • Mr. Chaim Lebovits, Pres & CEO (Age 47)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 41)
  • Mr. Eyal Rubin, Chief Financial Officer
  • Dr. Ralph Z. Kern M.D., MHSc, COO & Chief Medical Officer (Age 60)

Has Brainstorm Cell Therapeutics been receiving favorable news coverage?

News coverage about BCLI stock has been trending positive this week, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 0.46 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $3.30.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $64.84 million. The biotechnology company earns $-4,950,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Brainstorm Cell Therapeutics employs 24 workers across the globe.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1745 BROADWAY 17TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]


MarketBeat Community Rating for Brainstorm Cell Therapeutics (BCLI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Brainstorm Cell Therapeutics in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 172.73%. The high price target for BCLI is $9.00 and the low price target for BCLI is $9.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$9.00
Price Target Upside: 172.73% upside174.39% upside204.05% upside122.77% upside

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Consensus Price Target History

Price Target History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018Maxim GroupSet Price TargetBuy$9.00HighView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earnings History and Estimates Chart

Earnings by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.17)($0.17)($0.17)
Q4 20181($0.20)($0.20)($0.20)

Brainstorm Cell Therapeutics (NASDAQ BCLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018($0.32)N/AView Earnings Details
3/8/2018Q4 2017($0.09)$0.02ViewListenView Earnings Details
10/17/2017Q3 2017($0.16)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.10)($0.06)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.30)($0.10)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.07)($0.0330)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.11)($0.09)ViewN/AView Earnings Details
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
3/10/2016Q415($0.15)($0.07)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.12)($0.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Brainstorm Cell Therapeutics (NASDAQ BCLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 9.55%
Insider Trading History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Institutional Ownership by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ BCLI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018June Sherie AlmenoffDirectorBuy5,700$3.50$19,950.00View SEC Filing  
3/15/2018Ralph Dr. KernCOOBuy5,000$3.60$18,000.00View SEC Filing  
8/31/2017Irit ArbelDirectorBuy2,500$4.26$10,650.00155,833View SEC Filing  
8/23/2017Uri YablonkaEVPBuy2,000$3.98$7,960.007,543View SEC Filing  
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.0028,399View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.208,666View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.4050,408View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00138,806View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00136,806View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.0050,000View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Brainstorm Cell Therapeutics (NASDAQ BCLI) News Headlines

Source:
DateHeadline
BrainStorm Cell Therapeutics to Present at ARMs 6th Annual Cell & Gene Therapy Investor Day, April 17 in New YorkBrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
finance.yahoo.com - April 19 at 8:16 AM
 Brokerages Anticipate Brainstorm Cell Therapeutics (BCLI) to Announce -$0.14 EPS Brokerages Anticipate Brainstorm Cell Therapeutics (BCLI) to Announce -$0.14 EPS
www.americanbankingnews.com - April 16 at 11:10 PM
Brainstorm Cell Therapeutics (BCLI) Upgraded to Hold at ValuEngineBrainstorm Cell Therapeutics (BCLI) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 6:58 PM
 Analysts Anticipate Brainstorm Cell Therapeutics (BCLI) to Post -$0.14 EPS Analysts Anticipate Brainstorm Cell Therapeutics (BCLI) to Post -$0.14 EPS
www.americanbankingnews.com - March 31 at 1:16 AM
Brainstorm Cell Therapeutics (BCLI) Announces Phase 3 Trial of NurOwn in ALS Now Open to Canadian PatientsBrainstorm Cell Therapeutics (BCLI) Announces Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients
www.streetinsider.com - March 28 at 5:19 PM
Brainstorm Cell Therapeutics (BCLI) Given a $9.00 Price Target by Maxim Group AnalystsBrainstorm Cell Therapeutics (BCLI) Given a $9.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 28 at 10:58 AM
BrainStorm Cell Therapeutics Phase 3 Trial of NurOwn® in ALS Now Open to Canadian PatientsBrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients
finance.yahoo.com - March 28 at 8:27 AM
Brainstorm Cell Therapeutics (BCLI) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - SlideshowBrainstorm Cell Therapeutics (BCLI) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - Slideshow
seekingalpha.com - March 26 at 5:18 PM
Brainstorm Cell Therapeutics (BCLI) Earns Buy Rating from Maxim GroupBrainstorm Cell Therapeutics (BCLI) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - March 21 at 2:51 PM
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its ... - PR Newswire (press release)BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:48 AM
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory BoardBrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
finance.yahoo.com - March 21 at 8:48 AM
Insider Buying: Brainstorm Cell Therapeutics (BCLI) Director Purchases 5,700 Shares of StockInsider Buying: Brainstorm Cell Therapeutics (BCLI) Director Purchases 5,700 Shares of Stock
www.americanbankingnews.com - March 20 at 2:32 PM
Insider Buying: Brainstorm Cell Therapeutics (BCLI) COO Buys 5,000 Shares of StockInsider Buying: Brainstorm Cell Therapeutics (BCLI) COO Buys 5,000 Shares of Stock
www.americanbankingnews.com - March 20 at 1:25 PM
Brainstorm Cell Therapeutics (BCLI) Downgraded to "Sell" at ValuEngineBrainstorm Cell Therapeutics (BCLI) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 19 at 11:48 PM
ValuEngine Upgrades Brainstorm Cell Therapeutics (BCLI) to "Hold"ValuEngine Upgrades Brainstorm Cell Therapeutics (BCLI) to "Hold"
www.americanbankingnews.com - March 18 at 8:16 PM
Brainstorm Cell Therapeutics Inc (BCLI) to Post Q1 2018 Earnings of ($0.14) Per Share, Zacks Investment Research ForecastsBrainstorm Cell Therapeutics Inc (BCLI) to Post Q1 2018 Earnings of ($0.14) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - March 16 at 8:52 AM
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum - PR Newswire (press release)BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:19 AM
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor ForumBrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
finance.yahoo.com - March 15 at 6:12 PM
BCLI: Phase 3 Trial in ALS Enrolling PatientsBCLI: Phase 3 Trial in ALS Enrolling Patients
finance.yahoo.com - March 13 at 7:17 PM
BrainStorm Cell Therapeutics (BCLI) CEO Chaim Lebovits on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaBrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 11 at 8:14 AM
Maxim Group Analysts Give Brainstorm Cell Therapeutics (BCLI) a $9.00 Price TargetMaxim Group Analysts Give Brainstorm Cell Therapeutics (BCLI) a $9.00 Price Target
www.americanbankingnews.com - March 8 at 9:24 PM
Brainstorm Cell Therapeutics (BCLI) Announces Quarterly  Earnings ResultsBrainstorm Cell Therapeutics (BCLI) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 8 at 9:58 AM
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017 - PR Newswire (press release)BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017 - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:23 AM
Brainstorm Cell Therapeutics Inc. to Host Earnings CallBrainstorm Cell Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 8:23 AM
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
finance.yahoo.com - March 8 at 8:23 AM
Brainstorm Cell Therapeutics (BCLI) Scheduled to Post Quarterly Earnings on ThursdayBrainstorm Cell Therapeutics (BCLI) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 6 at 9:19 AM
BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8
finance.yahoo.com - March 5 at 8:17 AM
 Brokerages Expect Brainstorm Cell Therapeutics Inc (BCLI) Will Post Earnings of -$0.09 Per Share Brokerages Expect Brainstorm Cell Therapeutics Inc (BCLI) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 24 at 11:14 PM
ALS patients are unhappy with how $115 million raised by the Ice Bucket Challenge is being spentALS patients are unhappy with how $115 million raised by the Ice Bucket Challenge is being spent
finance.yahoo.com - February 14 at 9:43 AM
Corvus Pharmaceuticals (CRVS) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head ReviewCorvus Pharmaceuticals (CRVS) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head Review
www.americanbankingnews.com - February 11 at 8:10 AM
Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.comBrainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.com
www.streetinsider.com - February 5 at 3:40 PM
Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.comBrainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.com
www.streetinsider.com - February 5 at 3:40 PM
Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD to BoardBrainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD to Board
www.streetinsider.com - February 5 at 9:34 AM
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of DirectorsBrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
finance.yahoo.com - February 5 at 9:34 AM
Brainstorm Cell Therapeutics (BCLI) versus Its Peers Critical ComparisonBrainstorm Cell Therapeutics (BCLI) versus Its Peers Critical Comparison
www.americanbankingnews.com - January 12 at 1:18 AM
Analyzing Brainstorm Cell Therapeutics (BCLI) and Its CompetitorsAnalyzing Brainstorm Cell Therapeutics (BCLI) and Its Competitors
www.americanbankingnews.com - January 9 at 1:42 PM
-$0.09 EPS Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter-$0.09 EPS Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter
www.americanbankingnews.com - January 5 at 5:28 AM
BCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in IsraelBCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in Israel
finance.yahoo.com - January 4 at 3:24 PM
BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®
finance.yahoo.com - January 3 at 11:06 AM
Analysts Anticipate Brainstorm Cell Therapeutics Inc (BCLI) to Post ($0.09) EPSAnalysts Anticipate Brainstorm Cell Therapeutics Inc (BCLI) to Post ($0.09) EPS
www.americanbankingnews.com - December 29 at 11:30 PM
Brainstorm Cell Therapeutics (BCLI) Upgraded to "Hold" at ValuEngineBrainstorm Cell Therapeutics (BCLI) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 29 at 9:26 PM
Brainstorm Issues 2017 Letter to ShareholdersBrainstorm Issues 2017 Letter to Shareholders
finance.yahoo.com - December 29 at 9:26 AM
Brainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim GroupBrainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim Group
www.americanbankingnews.com - December 27 at 4:10 PM
Brainstorm Cell Therapeutics (BCLI) Lowered to Sell at ValuEngineBrainstorm Cell Therapeutics (BCLI) Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 21 at 11:26 PM
BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech ... - PR Newswire (press release)BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech ... - PR Newswire (press release)
www.prnewswire.com - December 20 at 7:47 AM
BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech ShowcaseBrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase
finance.yahoo.com - December 20 at 7:47 AM
Brainstorm Cell Therapeutics (BCLI) versus The Competition Head-To-Head ReviewBrainstorm Cell Therapeutics (BCLI) versus The Competition Head-To-Head Review
www.americanbankingnews.com - December 20 at 7:14 AM
-$0.09 Earnings Per Share Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter-$0.09 Earnings Per Share Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter
www.americanbankingnews.com - December 19 at 7:08 PM
Reviewing Brainstorm Cell Therapeutics (BCLI) & Its RivalsReviewing Brainstorm Cell Therapeutics (BCLI) & Its Rivals
www.americanbankingnews.com - December 16 at 11:08 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Expected to Post Earnings of -$0.09 Per ShareBrainstorm Cell Therapeutics Inc. (BCLI) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - December 1 at 11:34 PM

SEC Filings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Brainstorm Cell Therapeutics (NASDAQ BCLI) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.